Response to Lamivudine Treatment in Children with Chronic Hepatitis B Virus Infection

Despite the recent approval of lamivudine for the treatment of children with chronic hepatitis B virus (HBV) infection, there is insufficient information on the kinetics of HBV clearance and the factors that predict a favorable treatment response to lamivudine in this population. In a small retrospe...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2003-12, Vol.37 (11), p.1434-1440
Main Authors: Hagmann, Stefan, Chung, May, Rochford, Gemma, Jani, Mudra, Trinh-Shevrin, Chau, Sitnitskaya, Yekaterina, Neumann, Avidan U., Pollack, Henry
Format: Article
Language:English
Subjects:
Adolescent
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Biological and medical sciences
Cercopithecine herpesvirus 1
Child
Child health services
Child, Preschool
Children
Chronic hepatitis
DNA, Viral - drug effects
Drug Resistance, Viral
Female
Hepatitis antigens
Hepatitis B
Hepatitis B e Antigens - metabolism
Hepatitis B virus
Hepatitis B virus - drug effects
Hepatitis B virus - physiology
Hepatitis B, Chronic - drug therapy
Human viral diseases
Humans
Infections
Infectious diseases
Lamivudine - adverse effects
Lamivudine - therapeutic use
Major Articles
Male
Medical sciences
Pharmacology. Drug treatments
Retrospective Studies
Reverse Transcriptase Inhibitors - adverse effects
Reverse Transcriptase Inhibitors - therapeutic use
Transponders
Viral diseases
Viral hepatitis
Viral Load
Virus Replication - drug effects
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the recent approval of lamivudine for the treatment of children with chronic hepatitis B virus (HBV) infection, there is insufficient information on the kinetics of HBV clearance and the factors that predict a favorable treatment response to lamivudine in this population. In a small retrospective study of 16 HBV-infected children treated with lamivudine, we examined changes in virus load and other factors associated with hepatitis B e antigen (HBeAg) clearance. High pretherapy alanine aminotransferase level, low serum HBV DNA load, and age at the start of treatment were independently associated with HBeAg clearance. HBeAg clearance was also associated with the achievement of specific levels of virus suppression, and failure to achieve those levels was associated with the development of lamivudine resistance. Additional studies are necessary to provide better indications and guidelines for the treatment of children with chronic HBV infection.
ISSN:1058-4838
1537-6591
DOI:10.1086/378739